Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
| ▸ | GGT1 | P19440 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28090114 | 1.00 | CA2 (0.42) | CA2CA4CA1GABRR1LMNA | |
| Ethylenediamine SCHEMBL8741929 | 0.82 | GGT1 (0.47) | CA2CA4GABRR1LMNATDP1 | |
| SCHEMBL381772 | 0.82 | GGT1 (0.56) | CA2CA4GABRR1LMNATDP1 | |
| SCHEMBL692576 | 0.82 | GGT1 (0.56) | CA2CA4GABRR1LMNATDP1 | |
| SCHEMBL7091886 | 0.82 | GGT1 (0.56) | CA2CA4GABRR1LMNATDP1 | |
| Water SCHEMBL25415254 | 0.80 | GGT1 (0.55) | CA2CA4GABRR1LMNAGGT1 | |
| SCHEMBL1446361 | 0.80 | GGT1 (0.55) | CA2CA4GABRR1LMNAGGT1 | |
| SCHEMBL414800 | 0.80 | CA2 (0.45) | CA2CA4TDP1SMN1; SMN2GGT1 | |
| SCHEMBL15637714 | 0.80 | CA2 (0.45) | CA2CA4TDP1SMN1; SMN2GGT1 | |
| SCHEMBL5825896 | 0.80 | CA2 (0.45) | CA2CA4TDP1SMN1; SMN2GGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-08-02 | — | — | US | disclosed |
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | HLA-DRB1, MICA, CD74 | CA2 714/4885CA4 559/4885CA1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.